SparkRx
Big Health (formerly Limbix)
Digital therapeutic for teen and young adult depression
Decision Summary
- Solo and small practices
- Solo Practice, Group Practice
- Custom pricing - contact vendor
- Enterprise pricing - contact vendor
- No listed EHR integrations
About SparkRx
SparkRx is the first digital therapeutic designed specifically for adolescents and young adults ages 13-22 with symptoms of depression. Developed by Limbix (acquired by Big Health in 2023), the app delivers a multi-week program based on cognitive behavioral therapy (CBT) and behavioral activation protocols. The self-guided treatment teaches skills including mood tracking, behavioral activation, problem solving, and mindfulness, designed to complement treatment by a clinician. Clinical trials demonstrated a 21% remission rate compared to 4% for control groups, with treatment response rates of 29% versus 16%. Big Health acquired Limbix to expand their evidence-based digital therapeutics into adolescent mental health.
Best For
- • Child psychiatrists
- • adolescent psychologists
- • and school-based mental health providers treating teens and young adults ages 13-22 with depression symptoms
Not Ideal For
- • Patients with severe depression requiring hospitalization or those outside the 13-22 age range
Pricing
Contact for pricing
Compliance & Security
Always verify compliance directly with the vendor.
Target Audience
Roles
Settings
Related Tools
SleepioRx
FDA-cleared CBT-I digital therapeutic for insomnia
DaylightRx
FDA-cleared CBT digital therapeutic for anxiety
Akili Interactive (EndeavorRx, EndeavorOTC)
First FDA-cleared video game digital therapeutic for ADHD in children and adults.
Big Health (Sleepio, Daylight)
First FDA-cleared DTx for anxiety (DaylightRx) and insomnia (SleepioRx) with Medicare coverage.
Looking for alternatives?
Compare SparkRx with similar tools and find the best fit for your practice.